Page last updated: 2024-08-21

isoxazoles and Ankylosing Spondylarthritis

isoxazoles has been researched along with Ankylosing Spondylarthritis in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (77.78)	29.6817
2010's	2 (22.22)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Al-Mossawi, MH; Bowness, P; Brennan, PE; de Wit, J; Fedorov, O; Hammitzsch, A; Hay, DA; Knapp, S; Martinez, FO; Müller, S; O'Mahony, A; Tallant, C; Vecellio, M; Wells, C; Wordsworth, P	1
Goh, L; Samanta, A	1
Chang, YJ; Chen, LA; Hsu, YL; Su, LH; Tsai, TH	1
Braun, J; Haibel, H; Rudwaleit, M; Sieper, J	1
de Ryck, YM; Dijkmans, BA; Nurmohamed, MT; van Denderen, JC; van der Horst-Bruinsma, IE; van der Paardt, M	1
Maksymowych, WP	1
de Koning, MH; Dijkmans, BA; Nurmohamed, MT; Peters, MJ; Twisk, JW; van de Stadt, RJ; van Denderen, JC; van der Horst-Bruinsma, IE; van der Paardt, M; van Halm, VP	1
Braun, J; Sieper, J	1
Alessi, E; Barbareschi, M; Del Papa, N; Marzano, AV; Ramoni, S	1

Reviews

3 review(s) available for isoxazoles and Ankylosing Spondylarthritis

Article	Year
A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatology international, 2009, Volume: 29, Issue:10 Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Diphosphonates; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Interleukin 1 Receptor Antagonist Protein; Isoxazoles; Leflunomide; Meta-Analysis as Topic; Methotrexate; Multicenter Studies as Topic; Pamidronate; Randomized Controlled Trials as Topic; Receptors, Interleukin-1; Receptors, Tumor Necrosis Factor; Spondylitis, Ankylosing; Steroids; Sulfasalazine; Tumor Necrosis Factor-alpha	2009
New-onset psoriasis associated with etanercept therapy. The Journal of dermatology, 2010, Volume: 37, Issue:4 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Etanercept; Humans; Immunoglobulin G; Isoxazoles; Leflunomide; Male; Methotrexate; Prednisolone; Psoriasis; Receptors, Tumor Necrosis Factor; Spondylitis, Ankylosing; Sulfasalazine; Tumor Necrosis Factor-alpha	2010
Novel therapies for ankylosing spondylitis. Current rheumatology reports, 2005, Volume: 7, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Biomarkers; Etanercept; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Severity of Illness Index; Spondylitis, Ankylosing; Treatment Outcome; Tumor Necrosis Factor-alpha	2005

Trials

3 trial(s) available for isoxazoles and Ankylosing Spondylarthritis

Article	Year
Six months open label trial of leflunomide in active ankylosing spondylitis. Annals of the rheumatic diseases, 2005, Volume: 64, Issue:1 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Psoriatic; Female; Humans; Isoxazoles; Leflunomide; Male; Middle Aged; Patient Dropouts; Severity of Illness Index; Spondylitis, Ankylosing; Treatment Outcome	2005
Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Annals of the rheumatic diseases, 2005, Volume: 64, Issue:12 Topics: Adult; Aged; Antirheumatic Agents; Double-Blind Method; Female; Humans; Isoxazoles; Leflunomide; Male; Middle Aged; Pain Measurement; Patient Compliance; Patient Dropouts; Pilot Projects; Severity of Illness Index; Spondylitis, Ankylosing; Treatment Outcome	2005
Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Annals of the rheumatic diseases, 2006, Volume: 65, Issue:11 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholesterol; Cholesterol, HDL; Double-Blind Method; Etanercept; Female; Humans; Immunoglobulin G; Isoxazoles; Leflunomide; Lipids; Male; Middle Aged; Receptors, Tumor Necrosis Factor; Severity of Illness Index; Spondylitis, Ankylosing; Triglycerides; Tumor Necrosis Factor-alpha	2006

Other Studies

3 other study(ies) available for isoxazoles and Ankylosing Spondylarthritis

Article	Year
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses. Proceedings of the National Academy of Sciences of the United States of America, 2015, Aug-25, Volume: 112, Issue:34 Topics: Adult; Aged; Arthritis, Psoriatic; Azepines; Benzimidazoles; Calorimetry; CD4-Positive T-Lymphocytes; Cells, Cultured; Crystallography, X-Ray; Drug Evaluation, Preclinical; Female; Gene Expression Regulation; Humans; Immunosuppressive Agents; Interleukin-17; Isoxazoles; Kinetics; Male; Middle Aged; Models, Molecular; Molecular Structure; p300-CBP Transcription Factors; Protein Conformation; Protein Structure, Tertiary; Recombinant Proteins; Spondylitis, Ankylosing; Structure-Activity Relationship; Th17 Cells; Triazoles	2015
[Spondylarthritides]. Zeitschrift fur Rheumatologie, 2006, Volume: 65, Issue:7 Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Child; Diagnostic Imaging; Etanercept; Female; HLA-B27 Antigen; Humans; Immunoglobulin G; Inflammatory Bowel Diseases; Infliximab; Isoxazoles; Leflunomide; Male; Methotrexate; Physical Therapy Modalities; Receptors, Tumor Necrosis Factor; Spine; Spondylarthritis; Spondylitis, Ankylosing; Sulfasalazine	2006
Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. Lupus, 2008, Volume: 17, Issue:4 Topics: Adjuvants, Immunologic; Adult; Antibodies, Antinuclear; Biopsy; Diagnosis, Differential; Erythema Multiforme; Female; Fluorescent Antibody Technique, Direct; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lupus Erythematosus, Cutaneous; Skin; Spondylitis, Ankylosing	2008